ProQinase enters integrated drug discovery partnership of new AML drug
We are proud to inform you about ProQinase, a subsidiary of Reaction Biology, entering a multi-year contract for an integrated drug discovery project together with South Korea-based Bionetix and Netherland-based MercachemSyncom.
The project encompasses all steps from target identification up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia (AML).
With our complete suite of oncology-related biochemical, biophysical, cell-based, and in vivo assays, we are well situated to assist clients in a comprehensive approach to early-stage drug discovery. MercachemSyncom will contribute to medicinal chemistry work.
The goal is to advance the project to the clinical phase by 2023.
Read the press release here.